Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
Status:
Withdrawn
Trial end date:
2018-01-09
Target enrollment:
Participant gender:
Summary
This is a Phase I, single-center, open label, prospective, single-arm, dose-escalation and
multi-dose study evaluating the use of ibrutinib in combination with dasatinib and prednisone
therapy.